Existing investor Center Laboratories Group contributed to Tot's series B round, which will fund development of its oncology treatments.

The digital therapy developer added $13m from backers including Digital Garage to a series C round already featuring Amgen and Merck Group.

Therachon has welcomed back Inserm Transfert Initiative for its series B round, led by Novo.

Founded by two UC Berkeley graduates, DNAlite Therapeutics has been backed by the university and its Berkeley Catalyst Fund.

Existing shareholder IP Group has returned to back an $84m series B round for Artios, which also attracted corporates Pfizer, Novartis, AbbVie and Merck Group.

ICL spinout Cagen raised an undisclosed sum from Imperial Innovations and UKI2S to commercialise protein nanocages for shielding therapeutic payloads.

LBNL scientific analysis spinout Newomics has been backed by Berkeley Catalyst Fund to develop a testing platform initially targeting medical and biotech applications.

Blood sampling technology developer Essenlix was co-founded by Stephen Chou, a professor of electrical engineering at Princeton University.

Scripps Research Institute spinout BlackThorn Therapeutics will use Yale's Gemini-Dot technology to identify drug targets for neurobehavioural disorders.

Novartis Venture Fund and Partners Innovation Fund both took part in a round that will fund the first human trials for the company's gene therapies.